TransCelerate Selects Cognizant for Shared Investigator Platform - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
TransCelerate Selects Cognizant for Shared Investigator Platform

Source: Applied Clinical Trials

Cognizant announced that it has been selected by TransCelerate BioPharma Inc. to develop a subscription-based platform to enable the pharmaceutical industry to bring standardization and consistency to clinical trials.

The Shared Investigator Platform, which will be built as an 'industry utility' and is built to enhance organizational productivity by providing investigators and site staff with a central, single access point to clinical trial information, enhancing accuracy, and reducing study start-up time. It will also help pharmaceutical companies to improve quality, regulatory compliance, process visibility, and capacity, while reducing investigator efforts related to training, document exchange, and support. In the future, the platform may provide regulators with an efficient electronic audit process and better insight into clinical trials.

Read the full release here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here